Block listing application

RNS Number : 3900R

ReNeuron Group plc

01 March 2023

 

ReNeuron Group plc

("ReNeuron" or "the Group" or the "Company")

Block listing application

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies , announces that an application has been made to the London Stock Exchange for a block listing of securities in respect of 5,254,368 Ordinary Shares of 1p each (the "New Ordinary Shares") to be admitted to trading on AIM. It is expected that admission will become effective on or around 2 March 2023.

The New Ordinary Shares will be issued when necessary, in order to satisfy the issue of shares pursuant to the exercise of options issued under the Company's share schemes. When issued, the New Ordinary Shares will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares of 1p each in the capital of the Company. 

  ENDS

Enquiries:

ReNeuron		www.reneuron.com/investors
Iain Ross, Chairman		Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking)		[phone]
Allenby Capital Limited (Joint Broker)		[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)		[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects.  ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit  www.reneuron.com

 

END

 

 

ALSQVLFLXLLBBBX